SEC Comment Letter 0000000000-24-001400 to Bone Biologics Corp (BBLG)
Bone Biologics Corp
Date: Feb. 5, 2024 · CIK: 0001419554 · Accession: 0000000000-24-001400
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276771
Letter
United States securities and exchange commission logo February 5, 2024 Jeffrey Frelick Chief Executive Officer Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Re:Bone Biologics Corporation Registration Statement on Form S-1 Filed January 30, 2024 File No. 333-276771 Dear Jeffrey Frelick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Alexander McClean, Esq.
Show Raw Text
United States securities and exchange commission logo
February 5, 2024
Jeffrey Frelick
Chief Executive Officer
Bone Biologics Corporation
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803
Re:Bone Biologics Corporation
Registration Statement on Form S-1
Filed January 30, 2024
File No. 333-276771
Dear Jeffrey Frelick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Alexander McClean, Esq.